Does zolpidem have anxiolytic effects or can it worsen anxiety?

Zolpidem Does Not Have Reliable Anxiolytic Effects and May Worsen Anxiety

Zolpidem is not indicated for anxiety treatment and can cause or worsen anxiety as an adverse effect, particularly during withdrawal or discontinuation. The FDA labeling explicitly warns that zolpidem can cause "abnormal thoughts and behavior" including anxiety, and lists anxiety as a recognized adverse reaction 1.

Key Evidence from FDA Labeling

The official FDA drug label for zolpidem clearly identifies anxiety as:

• A potential adverse behavioral change requiring immediate medical attention 1
• A documented side effect that warrants calling your healthcare provider 1
• Part of withdrawal symptoms that can occur 1-2 days after stopping the medication 1

The FDA specifically warns about "abnormal thoughts and behavior" with zolpidem, including anxiety, agitation, hallucinations, worsening of depression, and suicidal thoughts 1. These neuropsychiatric effects are serious enough to be highlighted in the warnings section of the prescribing information.

Clinical Trial Evidence

While zolpidem improved sleep outcomes in controlled trials, the American College of Physicians guideline evidence report notes that:

• Zolpidem was associated with serious adverse effects including confusion and cognitive impairment 2
• Observational data linked anxiolytic and hypnotic drugs (including zolpidem) with increased all-cause mortality 2
• The drug can cause psychiatric adverse events according to FDA medical reviews 2

Preclinical and Human Research Findings

The research evidence consistently demonstrates limited to absent anxiolytic effects:

• Animal studies show zolpidem lacks consistent anxiolytic activity: Multiple rodent models (conflict tests, elevated plus-maze, light/dark choice tests) demonstrated that zolpidem had "weaker and/or non-specific anxiolytic-like effects" compared to non-selective benzodiazepines, with effects often occurring only at motor-impairing doses 3

• One human volunteer study using CO₂ inhalation models showed some anxiolytic effect at 5mg in a generalized anxiety model, but this was less efficacious than alprazolam in panic-like conditions 4. This represents the only positive finding, and it's in an experimental setting, not clinical anxiety disorders.

• Rhesus monkey studies showed anti-conflict effects only emerged >25 minutes post-injection, suggesting any anxiolytic-like properties are delayed and inconsistent 5

Critical Safety Concerns Related to Anxiety

Withdrawal from zolpidem can cause severe anxiety and related symptoms:

• Case reports document anxiety, tension, and palpitations upon discontinuation 6
• Chronological withdrawal symptoms include anxiety, craving, and progression to seizures and hallucinations 7
• Patients with psychiatric comorbidities (including anxiety disorders) are at higher risk for neuropsychiatric adverse effects 8

Clinical Implications

Do not prescribe zolpidem for anxiety treatment. The drug:

1. Has no FDA indication for anxiety disorders
2. Can cause or exacerbate anxiety as a direct adverse effect
3. Produces anxiety during withdrawal, particularly with chronic use or higher doses
4. Shows minimal anxiolytic properties in research models, and when present, these are inconsistent and non-specific

Common pitfall: Patients may report subjective "relaxation" from zolpidem due to its sedative effects, but this is not true anxiolysis and comes with significant risks of dependence, tolerance, and withdrawal-induced anxiety 9, 6, 7.

If a patient with insomnia also has anxiety, address the anxiety disorder separately with evidence-based treatments (SSRIs, SNRIs, CBT) rather than relying on zolpidem's sedative properties, which may ultimately worsen the clinical picture through dependence and withdrawal effects.